Cyrille Huchon
Prof Cyrille Huchon is an expert in Gynecology at Hôpital Lariboisière (France). Cyrille Huchon has authored 251 publications, the most recent in 2026, and is an investigator in 8 clinical trials, 3 of them ongoing. SLR score: 695 (community average: 125). How the SLR is computed.
LeadR Profile
Gynecology
Subspecialties: Oncology - Surgery - Obstetrics
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2008 - 2026
Number : 251
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Transvaginal Drainage vs Laparoscopy for Tubo-Ovarian Abscess: A Randomized Clinical Trial. PMID 42776546 — abscess, drainage, surgical procedures, operative, ovary, laparoscopy, therapeutics | JAMA Surg | 2026 | 0 |
| Thromboprophylaxis, pain and organization: How do expert centers manage PIPAC's perioperative care? An international survey. PMID 42143535 — pain, perioperative care, biological monitoring, environmental monitoring, pressurized intraperitoneal aerosol chemotherapy | Eur J Surg Oncol | 2026 | 0 |
| Comparison of sentinel lymph node mapping with comprehensive lymphadenectomy in p53-mutated endometrial cancer: a prospective, multi-center, non-inferiority, open-label, de-escalation, randomized, controlled trial (Study Protocol - SENTIMETREP53). PMID 41796475 — lymph nodes, tomography, lymph node excision, positron-emission tomography, genital neoplasms, female, neoplasms, multiple chronic conditions, classification, sentinel lymph node, positron emission tomography computed tomography, genes, p53, lymph, morbidity, therapeutics, mutation, endometrial neoplasms | Int J Gynecol Cancer | 2026 | 0 |
| Systematic literature review and meta-analysis of postoperative complications of surgical management of vulvar cancer: what is the impact of frailty factors? PMID 41619338 — reproduction, vulvar neoplasms, neoplasms, obstetrics, obesity, risk factors, morbidity, frailty, postoperative complications | Eur J Obstet Gynecol Reprod Biol | 2026 | 0 |
| Alternatives to Synthetic Midurethral Slings in the Surgical Management of Female Stress Urinary Incontinence: Results of a National Survey. PMID 41677817 — stress, physiological, urologists, urinary incontinence, gynecologists | Int Urogynecol J | 2026 | 0 |
Clinical Studies 8
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
3 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| SENTInel Node Mapping Versus Comprehensive Lymphadenectomy in p53 Mutated Endometrial Cancer A Non Inferiority Randomized Trial NCT06900582 — genes, lymph nodes, lymph node excision, ureter, neoplasms, sentinel lymph node, biopsy, arteries, genes, p53, lymph, tissues, ligaments, sentinel lymph node biopsy, indocyanine green, anatomy, iliac artery, mutation, dissection, endometrial neoplasms, cervix uteri | N/A | Not yet recruiting | 2026 |
| Medico economic Evaluation of Robot assisted Laparoscopy Compared With Conventional Laparoscopy in Hysterectomy for Endometrial Cancer NCT06348719 — anticoagulants, emergencies, pain, hysterectomy, pain measurement, data collection, neoplasms, neoplasms by histologic type, cohort studies, laparoscopy, analgesics, work, records, therapeutics, learning, random allocation, learning curve, biological products, emergency service, hospital, consent forms, demography, prospective studies, medical records, endometrial neoplasms, surgeons, biological data, carcinoma | N/A | Recruiting | 2024 |
| PARa aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer NCT05581121 — radiotherapy, carcinoma, adenosquamous, lymph nodes, lymph node excision, uterine cervical neoplasms, brachytherapy, neoplasms, adenocarcinoma, laparoscopy, human papillomavirus 16, lymph, therapeutics, carcinoma | Phase 3 | Recruiting | 2023 |
LeadR Networks
Main global connection map